// Biotech and Pharma Therapeutics
Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble
August 20, 2025 / Jazz Saniona deal / Epilepsy drug development / Kv7.2 Kv7.3 activator / SAN2355 clinical pipeline / Next-generation seizure therapy
Jazz Pharmaceuticals acquired global rights to Saniona’s SAN2355, a Kv7.2/Kv7.3 activator designed to avoid safety issues seen with Potiga. The $42.5M deal strengthens Jazz’s epilepsy pipeline, aiming to advance SAN2355 into clinical trials by year-end.
Xoma adds fading Mural Oncology to portfolio of struggling biotechs
August 20, 2025 / Xoma acquisition / failed cancer trials / Mural Oncology / IL-2 therapy / biotech consolidation
Xoma acquires Mural Oncology for $36M after failed IL-2 cancer trials, adding to a portfolio of struggling biotechs. Mural’s nemvaleukin alfa showed no success in melanoma and ovarian cancer, prompting layoffs and strategic review.
4 Steps to Safely Implement AI in Healthcare and Pharmacy Operations
August 20, 2025 / AI in healthcare / pharmacy operations / patient-centered AI / ethical AI implementation / clinical workflow automation
Implementing AI in healthcare requires phased integration—starting with model validation, empowering teams, embedding AI into operations, and unlocking insights—while maintaining ethical oversight and human involvement to ensure safe, patient-centered care.
Hybrid reading strategy for screening mammography reduces radiologist workload
August 19, 2025 / AI mammography / hybrid reading strategy / breast cancer screening / radiologist workload / cancer detection accuracy
A Dutch study shows a hybrid AI-radiologist reading strategy for mammography cut radiologist workload by 38% without affecting cancer detection or recall rates, leveraging AI confidence scoring to determine when human review is necessary.
Why listening may be the most powerful medicine
August 20, 2025 / values-driven listening / patient-centered care / empathy in healthcare / provider-patient communication / healthcare system improvement
Values-driven listening” improves trust, care quality, and patient outcomes by fostering empathy, curiosity, and connection. Research shows active, compassionate listening supports clinical decision-making, patient engagement, and clinician resilience—making it a critical yet underutilized element in modern healthcare delivery.
// 4th Industrial Revolution
Johns Hopkins team develops a more reliable AI for early cancer detection
August 19, 2025 / AI cancer detection / liquid biopsy AI / Johns Hopkins research / early cancer diagnosis / MIGHT algorithm
Johns Hopkins researchers developed MIGHT, a novel AI method improving early cancer detection via liquid biopsy by enhancing sensitivity and specificity. MIGHT reduces false positives by integrating autoimmune and vascular disease data, outperforming traditional AI in reliability and clinical accuracy.
How AI scribes could usher in higher medical bills
August 20, 2025 / AI scribes / healthcare billing / ambient documentation / physician workload / medical cost increase
AI-powered ambient scribes promise to reduce clinician workload, but emerging evidence suggests they may unintentionally drive up healthcare costs by enabling more extensive documentation, which can justify higher billing codes and increase overall medical expenses.
Talkdesk and Epic Integrate to Automate Patient Outreach with AI
August 19, 2025 / AI patient outreach / Epic integration / healthcare automation / Talkdesk Advanced Dialer / digital patient engagement
Talkdesk’s integration with Epic automates patient outreach by connecting AI-powered dialing to Epic workflows, reducing manual tasks, enhancing care coordination, and improving patient engagement through efficient communication across digital and voice channels.
Innovaccer Launches AI-Powered Prior Authorization Solution: Flow Auth
August 19, 2025 / AI prior authorization / Innovaccer Flow Auth / clinician burnout / healthcare automation / revenue cycle management
Innovaccer’s Flow Auth automates prior authorization, reducing clinician workload and delays in care. The AI-powered platform streamlines documentation, submission, tracking, and appeals—improving productivity, lowering denial rates, and addressing a major contributor to physician burnout.
How We Are Fighting HIV Infection Using AI
August 19, 2025 / HIV prevention AI / PrEP access / EHR predictive modeling / Parkland Health HIV / machine learning HIV detection
Parkland Health and PCCI developed an AI/ML model that uses EHR data to identify high-risk individuals for HIV, enabling targeted outreach and increased PrEP uptake—helping close prevention gaps and reduce HIV incidence in resource-limited, high-burden communities.
// Business & Markets
EliseAI Raises $250M to Expand AI Automation in Healthcare
August 20, 2025 / AI healthcare automation / EliseAI funding / patient scheduling AI / healthcare administrative costs / AI prior authorization
EliseAI raised $250M to expand its AI platform that automates healthcare workflows like scheduling and prior authorizations, aiming to reduce administrative costs, improve patient communication, and streamline front-desk operations—enhancing both efficiency and care experience.
Walgreens expands specialty pharmacy offerings
August 18, 2025 /specialty pharmacy expansion / limited distribution drugs / Walgreens medication access / chronic disease treatment / HIV prevention therapy
Walgreens Specialty Pharmacy has expanded its limited distribution drug portfolio to 265 medications, adding treatments for leukemia, HIV prevention, and chronic skin conditions—enhancing access to complex, high-cost therapies for patients with chronic and serious illnesses.
Alzheimer’s disease market to reach $17 billion in 8MM by 2033
August 20, 2025 / Alzheimer’s disease market / disease-modifying therapies / aging population healthcare / amyloid beta drugs / Alzheimer’s treatment forecast
The Alzheimer’s disease market in eight major countries is projected to grow to $17B by 2033, driven by the launch of costly disease-modifying therapies, increasing prevalence from aging populations, and new symptomatic treatments for agitation and psychosis.
Medtronic adds 2 board seats, forms special committees
August 19, 2025 / Medtronic board changes / Elliott Investment Management / medical device innovation / healthcare M&A strategy / operational performance healthcare
Medtronic appointed two medtech-experienced directors and formed committees on growth and operations, in collaboration with Elliott Investment Management, to enhance M&A, R&D, and performance—aligning with strategic goals to boost innovation, streamline operations, and drive long-term earnings growth.
Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year
August 19, 2025 / Q2 pharma earnings / Eli Lilly obesity drugs / Pfizer COVID rebound / BMS oncology sales / Inflation Reduction Act impact
Several major U.S. pharma companies rebounded in Q2 2025 after weak Q1 earnings, led by Pfizer, BMS, and Eli Lilly. Growth was driven by oncology, cardiology, and metabolic drugs, despite ongoing pricing pressure and market shifts under the Inflation Reduction Act.
// Legal & Regulatory
Medtronic recall of heart vent catheters tied to 3 serious injuries
August 19, 2025 / Medtronic catheter recall / heart vent catheter / FDA early alert / cardiac surgery device risk / catheter shape retention issue
Medtronic recalled 232 lots of its DLP Left Heart Vent Catheters due to shape retention failures, linked to three serious injuries. The defect may delay procedures or risk heart tissue damage; FDA issued an early alert due to potential harm.
Rocket can resume gene therapy trial after FDA lifts hold
August 20, 2025 / gene therapy trial / Danon disease treatment / FDA clinical hold / Rocket Pharmaceuticals RP-A501 / cardiovascular gene therapy
The FDA lifted its clinical hold on Rocket Pharmaceuticals’ gene therapy trial for Danon disease after protocol adjustments, including a lower RP-A501 dose and removal of a C3 inhibitor, allowing the potentially first-in-class cardiovascular gene therapy study to resume.
FDA extends review of REGENXBIO’s Hunter syndrome therapy
August 18, 2025 / Hunter syndrome gene therapy / RGX-121 FDA review / REGENXBIO RGX-121 / neurodegenerative rare disease / gene therapy clinical data
The FDA extended its review of REGENXBIO’s RGX-121 gene therapy for Hunter syndrome to February 2026 to assess additional long-term data. The therapy targets neurodevelopmental decline in boys with this rare condition and has received multiple regulatory designations.
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
August 19, 2025 / Friedreich’s ataxia treatment / vatiquinone FDA rejection / PTC Therapeutics CRL / rare disease therapy / neurological drug approval
The FDA issued a Complete Response Letter to PTC Therapeutics, rejecting the NDA for vatiquinone in Friedreich’s ataxia due to insufficient efficacy data. PTC plans to engage with the FDA and may pursue another controlled clinical trial.
FDA grants Breakthrough Therapy Designation to lung cancer therapy
August 19, 2025 / EGFR lung cancer / Breakthrough Therapy Designation / antibody-drug conjugate / iza-bren NSCLC / Bristol Myers SystImmune
The FDA granted Breakthrough Therapy Designation to iza-bren, an antibody-drug conjugate from SystImmune and Bristol Myers Squibb, for advanced EGFR-mutated NSCLC patients resistant to prior therapies. Early data show promising tumor control and manageable side effects.
// Research & Development
Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP, Demonstrating Statistically Significant Improvement in Time to Treatment Failure
Researchers in Thailand developed a validated dynamic nomogram to predict long-term survival in brain abscess patients, identifying key prognostic factors such as age, coagulopathy, and infection markers. This personalized tool supports clinical decision-making and improves individualized patient care.
Is ketamine the answer for chronic pain? New findings cast doubt
August 18, 2025 / ketamine chronic pain / NMDA antagonists review / ketamine side effects / chronic pain treatment evidence / Cochrane ketamine findings
A Cochrane review of 67 trials finds no strong evidence supporting ketamine’s effectiveness for chronic pain and highlights significant side effects. Researchers urge caution and call for high-quality studies before expanding ketamine’s clinical use in chronic pain management.
Stealth Biotherapeutics Resubmits New Drug Application for Elamipretide for the Treatment of Barth Syndrome
August 18, 2025 / Barth syndrome treatment / elamipretide NDA resubmission / mitochondrial disease therapy / Stealth Biotherapeutics FDA / rare disease drug approval
Stealth Biotherapeutics resubmitted its NDA for elamipretide in Barth syndrome after addressing FDA concerns, including manufacturing compliance and post-marketing commitments. The therapy showed promising results in muscle strength and functional outcomes, supporting its potential for accelerated approval.
Celldex ends esophageal program despite hitting primary endpoint in phase 2 trial
August 20, 2025 / eosinophilic esophagitis trial / barzolvolimab Celldex / mast cell depletion / GI inflammation therapy / KIT inhibitor development
Celldex halted development of barzolvolimab for eosinophilic esophagitis despite meeting its primary endpoint of mast cell depletion, due to lack of symptom improvement. The findings may inform future KIT-targeting strategies for other GI diseases involving mast cell activity.
Scientists unlock the gene that lets bearded dragons switch sex
August 20, 2025 / bearded dragon genome / reptile sex determination / Amh gene discovery / temperature-dependent sex / ZW chromosome system
Two independent studies have identified Amh and Amhr2 as key genes in male sex determination in bearded dragons, using high-quality genome assemblies. This breakthrough clarifies how genetics and temperature interact in reptilian sex differentiation and informs broader vertebrate sex research.
// Politics
Leading pediatric group breaks with RFK Jr., recommends COVID shots for young kids
August 19, 2025 / AAP COVID guidance / infant vaccination recommendation / pediatric COVID-19 shots / RFK Jr vaccine stance / childhood immunization policy
The American Academy of Pediatrics now recommends COVID-19 vaccination for all children aged 6 to 23 months, citing vulnerability to severe illness. This stance opposes RFK Jr.’s claims and reinforces the importance of science-based childhood immunization policies.
MAHA leaders may take aim at pharma DTC advertising
August 20, 2025 / pharma DTC advertising / MAHA Commission policy / FDA ad oversight / telehealth marketing regulation / drug ad reform
Draft strategy documents from the MAHA Commission suggest increased FDA and FTC oversight of direct-to-consumer (DTC) pharma ads—especially on social media—amid growing concerns over deceptive telehealth marketing, though a full advertising ban remains unlikely without congressional action.
Congresswoman Bice talks potential research budget cuts at biotech traveling series
August 19, 2025 / NIH funding cuts / biomedical research Oklahoma / OMRF budget concerns / biotech policy debate / Congresswoman Bice biotech
During a biotech-focused event in Oklahoma City, Rep. Stephanie Bice avoided addressing proposed Trump Administration cuts to NIH funding, which could impact local institutions like the Oklahoma Medical Research Foundation and hinder recruitment and research progress in biomedical science.
Trump administration leaves biotech investors more wary than ever of funding mRNA vaccines
August 14, 2025 / mRNA vaccine funding / Trump administration biotech / BARDA grant termination / mRNA investor confidence / mRNA cancer therapeutics
Investor confidence in mRNA vaccine development has declined further after the Trump administration halted $500M in funding, citing safety and trust concerns. However, mRNA applications in therapeutic areas like cancer remain less affected and continue to attract interest.
White House’s Navarro Says Pharma Tariffs Likely Under Section 232 Probe
August 14, 2025 / pharma import tariffs / Section 232 investigation / U.S. drug supply chain / domestic drug manufacturing / Trump pharma policy
White House adviser Peter Navarro signaled likely tariffs on pharmaceutical imports under a Section 232 national security probe, aiming to reduce U.S. reliance on foreign drug ingredients and boost domestic manufacturing through strategic contracts and supply chain reforms.